December 28, 2016
Ono Pharmaceutical said on December 27 that it has filed an application seeking an additional indication for its PD-1 inhibitor Opdivo (nivolumab) for the treatment of unresectable, advanced or recurrent gastric cancer. In a PIII trial dubbed ONO-4538-12, Opdivo significantly...read more